Redmile Group, LLC's Net Worth

$755 Million

Who is Redmile Group, LLC?

Redmile Group, LLC has an estimated net worth of $755 Million. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, XERIS PHARMACEUTICALS INC, RayzeBio, Inc., Allakos Inc., Science 37 Holdings, Inc., PLIANT THERAPEUTICS, INC., Stoke Therapeutics, Inc., Absci Corp, Adagio Therapeutics, Inc., Gritstone Oncology, Inc., Entrada Therapeutics, Inc., Repare Therapeutics Inc., Allovir, Inc., IGM Biosciences, Inc., Verve Therapeutics, Inc., Nurix Therapeutics, Inc., Akero Therapeutics, Inc., Replimune Group, Inc., AMICUS THERAPEUTICS INC, FATE THERAPEUTICS INC, Kymera Therapeutics, Inc., Beam Therapeutics Inc., Augmedix, Inc., Neoleukin Therapeutics, Inc., Syros Pharmaceuticals, Inc., Atreca, Inc., VAPOTHERM INC, Shattuck Labs, Inc., TCR2 THERAPEUTICS INC., HOOKIPA Pharma Inc., Cabaletta Bio, Inc., Annexon, Inc., MedAvail Holdings, Inc., Aprea Therapeutics, Inc., ARRAY BIOPHARMA INC, and Zymeworks Inc..

SEC CIK

Redmile Group, LLC's CIK is 0001425738

Past Insider Trading and Trends

2020 was Redmile Group, LLC's most active year for acquiring shares with 41 total transactions. Redmile Group, LLC's most active month to acquire stocks was the month of May. 2019 was Redmile Group, LLC's most active year for disposing of shares, totalling 18 transactions. Redmile Group, LLC's most active month to dispose stocks was the month of September. 2020 saw Redmile Group, LLC paying a total of $190,530,705.65 for 23,089,273 shares, this is the most they've acquired in one year. In 2023 Redmile Group, LLC cashed out on 20,855,459 shares for a total of $77,321,731.46, their largest year based on trade value.